Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal Capsules

X
Trial Profile

Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal Capsules

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temozolomide (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma
  • Focus Pharmacokinetics; Registrational
  • Sponsors ORPHELIA Pharma
  • Most Recent Events

    • 09 Jan 2024 According to an ORPHELIA Pharma media release, an article of this study published in a Pharmaceutics.
    • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2022 According to an ORPHELIA Pharma media release, data from this trial was selected by the Scientific Program Committee of the 2022 ASCO annual meeting and was released online.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top